These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 30640701)

  • 1. Low grade serous ovarian carcinoma: identifying variations in practice patterns.
    Siemon J; Gershenson DM; Slomovitz B; Schlumbrecht M
    Int J Gynecol Cancer; 2019 Jan; 29(1):174-180. PubMed ID: 30640701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperthermic Intraperitoneal Chemotherapy after Secondary Cytoreduction in Epithelial Ovarian Cancer: A Single-center Comparative Analysis.
    Baiocchi G; Ferreira FO; Mantoan H; da Costa AA; Faloppa CC; Kumagai LY; de Mello CA; Takahashi RM; Nakagawa WT; Aguiar S; Lopes A
    Ann Surg Oncol; 2016 Apr; 23(4):1294-301. PubMed ID: 26628430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and the Risk of Platinum Resistance in Epithelial Ovarian Cancer.
    da Costa AA; Valadares CV; Baiocchi G; Mantoan H; Saito A; Sanches S; Guimarães AP; Achatz MI
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S971-8. PubMed ID: 26014155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian low-grade serous carcinoma involving the cervix mimicking a cervical primary.
    Malpica A; Deavers MT
    Int J Gynecol Pathol; 2011 Nov; 30(6):613-9. PubMed ID: 21979600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-grade serous ovarian carcinoma: an evolution toward targeted therapy.
    Voutsadakis IA
    Int J Gynecol Cancer; 2020 Oct; 30(10):1619-1626. PubMed ID: 31780569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
    Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?
    Fader AN; Bergstrom J; Jernigan A; Tanner EJ; Roche KL; Stone RL; Levinson KL; Ricci S; Wethingon S; Wang TL; Shih IM; Yang B; Zhang G; Armstrong DK; Gaillard S; Michener C; DeBernardo R; Rose PG
    Gynecol Oncol; 2017 Oct; 147(1):85-91. PubMed ID: 28768570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
    Silva EG; Gershenson DM; Malpica A; Deavers M
    Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer.
    Eng KH; Hanlon BM; Bradley WH; Szender JB
    Gynecol Oncol; 2015 Nov; 139(2):228-35. PubMed ID: 26383827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.
    Gershenson DM; Sun CC; Bodurka D; Coleman RL; Lu KH; Sood AK; Deavers M; Malpica AL; Kavanagh JJ
    Gynecol Oncol; 2009 Jul; 114(1):48-52. PubMed ID: 19361839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Survival for Platinum-Sensitive Recurrent Ovarian Cancer Patients Treated with Secondary Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
    Petrillo M; De Iaco P; Cianci S; Perrone M; Costantini B; Ronsini C; Scambia G; Fagotti A
    Ann Surg Oncol; 2016 May; 23(5):1660-5. PubMed ID: 26714958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-grade serous carcinoma: molecular features and contemporary treatment strategies.
    Angarita AM; Cholakian D; Fader AN
    Expert Rev Anticancer Ther; 2015; 15(8):893-9. PubMed ID: 26040191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-grade
    Cappuccio S; Marchetti C; Altıntaş DA; Oliva R; Russo SA; Costantini B; Giannarelli D; Quagliozzi L; Scambia G; Fagotti A
    Int J Gynecol Cancer; 2024 Feb; 34(2):293-299. PubMed ID: 38135438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer: a Korean gynecologic oncology group study (OV 1708).
    Chung YS; Park SY; Lee JY; Park JY; Lee JW; Kim HS; Suh DS; Kim YH; Lee JM; Kim M; Choi MC; Shim SH; Lee KH; Song T; Hong JH; Lee WM; Lee B; Lee IH
    BMC Cancer; 2019 Apr; 19(1):341. PubMed ID: 30971221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.
    Canaz E; Grabowski JP; Richter R; Braicu EI; Chekerov R; Sehouli J
    Gynecol Oncol; 2019 Sep; 154(3):539-546. PubMed ID: 31230821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment Outcomes of Epithelial Ovarian Cancers Following Maximum Cytoreduction and Adjuvant Paclitaxel-Carboplatin Chemotherapy: Egyptian NCI Experience.
    Nassar HR; Zeeneldin AA; Helal AM; Ismail YM; Elsayed AM; Elbassuiony MA; Moneer MM
    Asian Pac J Cancer Prev; 2015; 16(16):7237-42. PubMed ID: 26514517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The road to long-term survival: Surgical approach and longitudinal treatments of long-term survivors of advanced-stage serous ovarian cancer.
    Javellana M; Hoppenot C; Lengyel E
    Gynecol Oncol; 2019 Feb; 152(2):228-234. PubMed ID: 30471899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma: impact of optimal cytoreduction and standard adjuvant treatment.
    Yalcin I; Meydanli MM; Turan AT; Taskin S; Sari ME; Gungor T; Akbayir O; Ayhan A
    Int J Clin Oncol; 2018 Apr; 23(2):329-337. PubMed ID: 29143144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors and clinical outcome of patients with recurrent early-stage epithelial ovarian cancer: an Italian multicenter retrospective study.
    Gadducci A; Cosio S; Zola P; Sostegni B; Fuso L; Sartori E
    Int J Gynecol Cancer; 2013 Mar; 23(3):461-8. PubMed ID: 23370604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serous carcinomas.
    Gourley C; Farley J; Provencher DM; Pignata S; Mileshkin L; Harter P; Maenpaa J; Kim JW; Pujaide-Lauraine E; Glasspool RM; Ray-Coquard I; Gershenson D
    Int J Gynecol Cancer; 2014 Nov; 24(9 Suppl 3):S9-13. PubMed ID: 25341587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.